Precigen reports PAPZIMEOS revenue of $72.9 million in third quarter
Precigen said PAPZIMEOS net revenue rose 37% sequentially in the third quarter, while the company reported positive cash flow and continued pipeline development.
Precigen Inc. (Nasdaq:PGEN) reported PAPZIMEOS net revenue of $72.9 million for the third quarter, up 37% sequentially. The company also reported net income of $35.8 million, or $0.08 per diluted share, and said it achieved positive cash flow a quarter ahead of schedule.
Precigen said the period was its second consecutive profitable period. Cash, cash equivalents and investments stood at $51 million, while cumulative product revenue since the launch of PAPZIMEOS reached approximately $151 million.
The results were reported on November 10, 2026. The company attributed the performance to continued uptake of PAPZIMEOS, its treatment for adults with recurrent respiratory papillomatosis (RRP).
More than 500 patients had begun PAPZIMEOS treatment since its August 2025 approval, according to Precigen, and more than 300 patients had completed therapy.
The company said use was expanding across academic medical centres, infusion centres and community practices. Precigen also cited payer coverage for more than 315 million US lives, a permanent J-code and clinical data as factors supporting adoption.
RRP causes recurring airway tumours and has traditionally been treated through repeated surgeries. Precigen describes PAPZIMEOS as the first FDA-approved therapy for adults with the condition.
Precigen said PAPZIMEOS recorded a 51% complete response rate in its pivotal trial. The company defines a complete response as requiring no surgeries during the year following treatment.
Data presented at the American Academy of Otolaryngology-Head and Neck Surgery Foundation annual meeting showed ongoing complete responses for up to five years after treatment, according to the company. Precigen also said the pivotal trial recorded no treatment-related adverse events above Grade 2 and no dose-limiting toxicities.
A second RRP treatment recently received conditional FDA approval, Precigen said. That approval requires a confirmatory study to establish clinical benefit and used a surrogate endpoint based on reducing surgeries rather than the current standard of complete response.
Precigen said the competing product is anticipated to arrive at least a year and a half behind PAPZIMEOS and has an electroporation device with open FDA commitments. The company said the introduction of another therapy had been incorporated into its strategic planning, commercial modelling and investment decisions.
In September, Precigen said it received an FDA Platform Technology Designation for its AdenoVerse technology platform. The company said the designation could shorten development timelines for future programmes by allowing existing manufacturing and preclinical data to be used across multiple product candidates.
PRGN-2009 uses the same AdenoVerse vector backbone as PAPZIMEOS and is in Phase 2 trials for cancers associated with HPV 16 and HPV 18. One study is evaluating PRGN-2009 with pembrolizumab in newly diagnosed HPV oropharyngeal cancer in a neoadjuvant setting. A separate multicentre study is assessing the combination in recurrent or metastatic cervical cancer.
Precigen said a data update for the head and neck programme is expected at a forthcoming R&D Day.
Management identified several further development areas for PAPZIMEOS and the wider pipeline. These include a redosing study examining whether partial responders can transition into complete responders, paediatric development efforts and European expansion.
Regulators are reviewing PAPZIMEOS' marketing application in Europe. Precigen also said it would continue developing PRGN-2009.
Precigen Inc. reported third-quarter PAPZIMEOS net revenue of $72.9 million, net income of $35.8 million, or $0.08 per diluted share, and positive cash flow achieved a quarter ahead of schedule. The company also reported its second consecutive profitable period and cash, cash equivalents and investments of $51 million.
The report was dated November 10, 2026. It described Precigen Inc.'s third-quarter results and referred to an investor call held last week.
Precigen Inc. reported PAPZIMEOS net revenue of $72.9 million for the third quarter, up 37% sequentially. Cumulative product revenue since launch was approximately $151 million.
Precigen Inc. reported net income of $35.8 million, or $0.08 per diluted share, and said it achieved positive cash flow a quarter ahead of schedule. The company described the period as its second consecutive profitable period.
Precigen Inc. reported cash, cash equivalents and investments of $51 million at the end of the period covered.
Precigen Inc. said adoption was broadening across academic medical centres, infusion centres and community practices, supported by widespread payer coverage, a permanent J-code and favourable clinical data. The company said more than 500 patients had begun treatment since the August 2025 approval, with more than 300 patients completing therapy.
Precigen Inc. describes PAPZIMEOS as the first FDA-approved therapy for adults with recurrent respiratory papillomatosis, or RRP. The company says RRP causes recurring airway tumours and has traditionally been managed with repeated surgeries to remove them.
Precigen Inc. said PAPZIMEOS produced a 51% complete response rate in its pivotal trial, defined as patients requiring no surgeries during the year following treatment. The company also reported ongoing complete responses for up to five years after treatment, no treatment-related adverse events above Grade 2 and no dose-limiting toxicities in the pivotal trial.
Chief Executive Officer Helen Sabzevari said Precigen Inc.'s strategy was designed to establish leadership in RRP through PAPZIMEOS' efficacy, safety, durability and ease of administration, its regulatory foundation, its commercial infrastructure and the company's ability to execute. She said the introduction of a competing therapy had been anticipated in the company's strategic planning, commercial modelling and investment decisions.
Precigen Inc. said it received an FDA Platform Technology Designation for its AdenoVerse technology platform in September. The company said the designation could shorten development timelines for future programmes by allowing existing manufacturing and preclinical data to be leveraged across multiple product candidates.
Precigen Inc. said PRGN-2009 is in Phase 2 trials for cancers associated with HPV 16 and HPV 18, using the same AdenoVerse vector backbone as PAPZIMEOS. One trial is evaluating PRGN-2009 with pembrolizumab in newly diagnosed HPV oropharyngeal cancer, while another is evaluating the combination in recurrent or metastatic cervical cancer.
Precigen Inc. identified a redosing study to evaluate whether partial responders can transition into complete responders, paediatric development efforts and European expansion, where regulators are reviewing PAPZIMEOS' marketing application. The company also cited continued development of PRGN-2009 and said a data update in the head and neck programme is expected at a forthcoming R&D Day.
Precigen Inc.'s shares trade on Nasdaq under the ticker symbol PGEN, as stated in the source.